Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc (PBLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Expects interim data by early 2024...

PBLA : 0.3300 (-0.06%)
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.3300 (-0.06%)
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.3300 (-0.06%)
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction,...

PBLA : 0.3300 (-0.06%)
Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3300 (-0.06%)
Panbela Announces Poster Presentation at American Association for Cancer Research:

The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer...

PBLA : 0.3300 (-0.06%)
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to...

PBLA : 0.3300 (-0.06%)
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

PBLA : 0.3300 (-0.06%)
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET

MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3300 (-0.06%)
Panbela to Participate in the 34th Annual Roth Conference

MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3300 (-0.06%)

Barchart Exclusives

1 Growth Stock to Buy Now as the Fed Begins Its Rate-Cut Cycle
The Fed has kicked off its rate-cut cycle with a 50-basis point cut. SoFi looks like a good stock to buy, as the Fed's rate cuts could revive sagging growth in the U.S. economy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar